Alchemedicine Overview
- Founded
-
2019
- Status
-
Private
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$7.17M
- Investors
-
7
Alchemedicine General Information
Description
Provider of drug discovery services intended to treat diseases with unmet medical needs. The company's services actively work to create new drugs even in areas and diseases where drug discovery is seemingly difficult, enabling clients to deliver drugs that are useful to patients as soon as possible.
Contact Information
Website
www.alchemedicine.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
- 13-2 Higashiarai
- Ibaraki Prefecture
- Tsukuba City, 305-0033
- Japan
+81 000-000-0000
Alchemedicine Timeline
Alchemedicine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 16-Feb-2021 | $7.17M | 00.00 | 000.00 | Completed | Generating Revenue |
| 2. Early Stage VC (Series B) | 18-Oct-2019 | 00.000 | 00.00 | 00.000 | Completed | Startup |
| 1. Early Stage VC (Series A) | 14-Jun-2019 | $385K | $385K | 00.000 | Completed | Startup |
Alchemedicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Shares | 00,000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.00 | ||
| B Shares | 00,000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | ||
| A Shares | 15,000 | $26.78 | $26.78 | 1x | $26.78 | 8.71% |
Alchemedicine Patents
Alchemedicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021368547-A1 | Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug | Pending | 02-Nov-2020 | ||
| CA-3194020-A1 | Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug | Pending | 02-Nov-2020 | ||
| EP-4174061-A1 | Heterocyclic compound as inhibitor for casein kinase 1d and/or activin receptor-like kinase 5 | Pending | 25-Jun-2020 | 000000000 | |
| AU-2021296087-A1 | Heterocyclic compound as inhibitor for casein kinase 1δ and/or activin receptor-like kinase 5 | Pending | 25-Jun-2020 | 00000000000 | |
| CA-3182966-A1 | Heterocyclic compound as inhibitor for casein kinase 1.delta. and/or activin receptor-like kinase 5 | Pending | 25-Jun-2020 | A61K31/4439 |
Alchemedicine Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Keigo Tanaka | Chief Executive Officer, President & Chairman |
Alchemedicine Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Keigo Tanaka | Alchemedicine | Chief Executive Officer, President & Chairman | 000 0000 |
Alchemedicine Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Beyond Next Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Enjoyor Investment | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Jafco | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Joyo Capital Partners | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Mitsubishi UFJ Capital | Venture Capital | Minority | 000 0000 | 000000 0 |